Marrone Story

MBII -- USA Stock

USD 1.74 0.03 1.75%

Macroaxis Story

Despite nearly unsteady forward indicators, Marrone Bio may actually be approaching a critical reversion point that can send shares even higher in April 2021. We currently estimate Marrone Bio as undervalued. The real value is approaching 2.49 per share.

Published over three weeks ago

View all stories for Marrone Bio | View All Stories

Does Marrone Bio (NASDAQ:MBII) have stable forward indicators based on the current rise?

We provide investment recommendation to complement the last-minute expert consensus on Marrone Bio Innov. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Marrone Bio income statement, its balance sheet, and the statement of cash flows. Potential Marrone Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Marrone Bio investors may use each financial statement separately, they are all related. The changes in Marrone Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Marrone Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Marrone Bio fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Marrone Bio performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Marrone Bio shares is the value that is considered the true value of the share. If the intrinsic value of Marrone is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Marrone Bio.

Please read more on our fundamental analysis page.

Are Marrone Bio Earnings Expected to grow?

The future earnings power of Marrone Bio involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Marrone Bio factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Marrone Bio stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Marrone expected earnings.

How Marrone utilizes its cash?

To perform a cash flow analysis of Marrone Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Marrone Bio is receiving and how much cash it distributes out in a given period. The Marrone Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Marrone Bio Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (15.96 Million)

Marrone Bio Gross Profit

Marrone Bio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Marrone Bio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Marrone Bio Gross Profit growth over the last 10 years.

Please check Gross Profit in more details.

Exercise or conversion by Ospraie Ag Science Llc of 4264299 shares of Marrone Bio subject to Rule 16b-3

Legal trades by Marrone Bio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Marrone insider trading alert for exercise of warrant by Ospraie Ag Science Llc, the corporate stakeholder, on 16th of March 2021. This event was filed by Marrone Bio Innovations I with SEC on 2021-03-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Marrone Bio

Institutional investors typically avoid acquiring a high percentage of Marrone Bio stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Marrone is distributed among investors.

Ownership Allocation

Marrone Bio Innov holds a total of 171.74 Million outstanding shares. The majority of Marrone Bio outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Marrone Bio Innov to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Marrone Bio Innov. Please pay attention to any change in the institutional holdings of Marrone Bio as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors

19.79%

Institutions

79.3%

	Retail Investors	19.79
	Insiders	0.91
	Institutions	79.3

	2018	2019	2020	2021 (projected)
Revenues USD	21.22 M	29.37 M	33.78 M	36.45 M
Revenues	21.22 M	29.37 M	33.78 M	36.45 M

Revenues USD Revenues

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Marrone Bio has an asset utilization ratio of 74.34 percent. This implies that the company is making $0.74 for each dollar of assets. An increasing asset utilization means that Marrone Bio Innov is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets

24.8 M

Assets Non Current

63.3 M

Goodwill

27.4 M

Current Assets	24.8 Million	21.48
Assets Non Current	63.28 Million	54.81
Goodwill	27.38 Million	23.72

Another setback for Marrone Bio stockholders

Downside deviation is down to 3.22. It may hint to a possible volatility drop. Marrone Bio Innov shows above-average downside volatility for the selected time horizon. We advise investors to inspect Marrone Bio Innov further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Marrone Bio future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Marrone Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Marrone Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Marrone Bio Innov

While some other companies within the agricultural inputs industry are still a little expensive, even after the recent corrections, Marrone Bio may offer a potential longer-term growth to stockholders. In closing, as of the 23rd of March 2021, we believe that at this point, Marrone Bio is undervalued with below average odds of distress within the next 2 years. Our primary buy-sell recommendation on the company is Strong Buy.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Marrone Bio Innov. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC